Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT04243005
Active, not recruiting Not applicable

Supramarginal Resection in Glioblastoma

NCT04243005 · tracked via the Priya Life Science Sweden tracker
Sponsor
St. Olavs Hospital
Phase
Not applicable
Started
2020-07-01
Last updated
2026-03-03

Condition(s) studied

Glioblastoma

Investigational drug(s) / intervention(s)

Supramarginal resectionConventional surgery

Supramarginal resection: Aim of supramarginal resection, where a margin of at least 10 mm is considered feasible prior to surgery. The resection is guided by the T2 volume (i.e. zone of edema) where removal of as much as possible of this zone (or beyond) is attempted as long as considered safe

Conventional surgery: Aim of gross total resection (i.e. removal of contrast enhancing tumor) according to institutional practice. No limit in use of technical adjuncts in this arm.

Study summary

Gliomas are the most common malignant brain tumor. Glioblastoma, WHO grade IV astrocytoma, is the most common subtype and unfortunately also the most aggressive subtype with median survival in population based cohorts being only 10 months. Extensive surgical resections followed by postoperative fractioned radiotherapy and concomitant and adjuvant temozolomide prolong survival and is the standard treatment.

The investigators think there is significant potential in individualized surgical decision-making in glioblastoma management. The idea that some patients are amendable to radical surgery, while others should be treated more conservatively, is not controversial in other fields of oncology. The current concept in all patients with glioblastoma is "maximum safe resection of the contrast enhancing tumor", but this may in selected cases be extended to simply "maximum safe resection" tailored to the patient and extent of disease at hand.

Densely proliferating tumor cells have been found from at an average of 10 mm beyond the margins of contrast enhancement in high-grade gliomas. There are now several case series, using various definitions of supramarginal resection, but they have in common that they report a benefit of resection with a margin. This potential benefit also comes together with an associated neurological risk, making this approach unethical and simply not feasible in the patients with glioblastoma as a whole.

Objective of this study is: To investigate if resection with a margin, that is significantly beyond the radiological contrast enhancement, improves survival in selected patients with glioblastoma.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. A suspected diagnosis of supratentorial glioblastoma by MRI.(A) 2. Indication for surgical treatment and where supramarginal resection is considered possible according to the preoperative imaging. This consideration needs to be verified by two specialists in neurosurgery. 3. Negative work-up for other primary tumor(B) 4. Karnofsky performance status of 70 - 100. A) If randomized to supramarginal surgery, intraoperative frozen section must conclude with "high-grade glioma" to be able to proceed. Surgery in two sessions is also possible in supramarginal group if there is no intraoperative frozen section available or frozen section indicate another diagnosis, but final histopathology reveals a glioblastoma. In case of surgery in two session, there must be no more than 30 days between procedures. See flow-chart in attachment 1. B) No suspected primary tumor seen on CT chest, abdomen and pelvis. If relevant symptoms/clinical suspicion also supplement with mammography, dermatologist exam, relevant endoscopies etc. Exclusion Criteria: 1. Not willing to be randomized. 2. Informed consent not possible (e.g. language barriers, aphasia, cognitive severely impaired). 3. Contrast enhancement volume bilateral OR involving corpus callosum. 4. Contrast enhancement along the ependymal lining of ventricles (contact is however not an exclusion criteria). 5. Contrast enhancement involving several lobes. 6. History of major psychiatric disorder such as psychosis, schizophrenia and/or mood disorder (e.g. depression and bipolar disorder) in need of hospitalization 7. Unfit for participation for any other reason judged by the including physician

Primary outcome measure(s)

Trial sites (17)

FacilityCityRegionStatus
Medical University of Vienna Vienna Austria
Odense University Hospital Odense Denmark
Helsinki University Hospital Helsinki Finland
Kuopio University Hospital Kuopio Finland
Oulu University Hospital Oulu Finland
Tampere University Hospital Tampere Finland
Turku University Hospital Turku Finland
Erasmus MC Rotterdam Netherlands
Haaglanden MC The Hague Netherlands
Haukeland University Hospital Bergen Norway
Oslo University Hospital, Rikshospitalet Oslo Norway
Ullevål University Hospital Oslo Norway
St Olavs Hospital Trondheim Norway
Sahlgrenska University Hospital, Gothenburg Sweden
Karolinska University Hospital Stockholm Sweden
University Hospital of Umeå Umeå Sweden
Uppsala University Hospital Uppsala Sweden

More St. Olavs Hospital trials in Sweden

Innovative Steroid Treatment to Reduce Asthma Development in Children After First-time Rhinovirus Induced Wheezing Recruiting
Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas Active, not recruiting

Other trials for the same condition

Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma Recruiting
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM Recruiting
Surgery for Recurrent Glioblastoma Recruiting
Impact of Salovum® and SPC® Flakes on Brain Tumor Induced Edema Recruiting
Antisecretory Factor Glioblastoma Phase 2 Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04243005 on ClinicalTrials.gov ↗ ← All trials in Sweden